

Pharmaceutical Executive
Pharmaceutical Executive Podcast
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Episodes
Mentioned books

Aug 9, 2022 • 24min
Behind the Creative….Inspiring Award Winning Creative with Halen Dang and Carrie Morris
Proximyl Health’s Halen Dang, VP, Creative Director of Art and Carrie Morris, VP, Creative Director of Copy discuss remote teamwork and how to successfully lead agency creative teams with hybrid schedules.

Aug 4, 2022 • 17min
Managing Workplace Stress
In episode 114, Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses why it’s important to manage high levels of workplace stress, and how companies can help employees in need.
Listen to the latest episode of The Pharmaceutical Commerce Podcast: https://www.pharmaceuticalcommerce.com/view/making-the-commercialization-process-worthwhile

Jul 21, 2022 • 13min
Serving The Patient
In episode 113, Indranil Bagchi, senior vice president and worldwide head, value and access at Novartis, and member of Pharmaceutical Executive Editorial Advisory Board, discusses the challenges of reaching patients and what he believes can help improve the situation.
Listen to the latest Pharmaceutical Commerce podcast: bit.ly/3uyWD8d

Jul 19, 2022 • 22min
Behind the Creative…Inspiring Award Winning Creative Carolyn O’Neill
Carolyn O’Neill, Chief Creative Officer of Centron discusses their APEX-award winning global disease awareness campaign for both HCPs and patients, “Dimensionalizing the Patient Experience in PNH.” PNH or paroxysmal nocturnal hemoglobinuria is a rare immune disorder that attacks a person’s red blood cells. The campaign was meant to build on it is not an inherited disease and people’s symptoms don’t exhibit externally, usually appearing in mid-life and portray the feelings of a PNH sufferer.

Jul 7, 2022 • 12min
Emerging Successful
Nima Farzan, CEO of Kinnate, who was one of Pharmaceutical Executive’s Emerging Pharma Leaders in 2013, discusses how he’s successfully navigated his career path, from building a foundation in pharma to growing his expertise in biotech.
Listen to the latest Pharmaceutical Commerce podcast: https://bit.ly/3uyWD8d

Jun 29, 2022 • 20min
Behind the Creative…Inspiring Award Winning Creative with Omair Ahmed
Nexus Pharmaceuticals' Chief Strategy Officer Omair Ahmed discusses their APEX-award winning EMERPHED™ campaign, which built on the ideas of simplification, safety and stability to enhance their hospital-delivered product and support their field sales reps.

Jun 23, 2022 • 18min
Creating A Space For Women’s Health
Kevin Ali, CEO of Organon, talks about how’s he’s lead the launch of a new niche company for women’s health, and what he hopes it can achieve.

Jun 9, 2022 • 16min
Inside The Metaverse For Pharma
Ken Winell, chief technology officer of Greater Than One, talks about the metaverse and the potential it has to serve the pharma industry.

Jun 8, 2022 • 28min
Behind the Creative…Inspiring Award Winning Creative with John England
CDM Princeton’s Senior Creative Vice President John England discuss the company’s APEX-award winning Ilumya campaign “Defy the Laws of Psoriasis,” which used multiple innovative ideas including an AR focused in-person interactive piece, a upward scrolling website and more.

May 26, 2022 • 22min
New Guidance For Biopharma Investor ESG Communications
Myrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.


